source
- MPM has collected three China drugs for its ‘best of both worlds’ strategyMPM BioImpact, a leading biotech investor, is going all in on its strategy to take China-born drugs to the global stage. Over the past year, its portfolio company K2 Therapeutics has amassed three…Endpoints · 3mo ago↗ source
- AstraZeneca cuts a couple of late-stage life-cycle trials after disappointing efficacyAstraZeneca said it had stopped several mid- and late-stage trials of some of its pipeline programs in the past few months, potentially limiting some of the life-cycle extensions it was hoping for.…Endpoints · 3mo ago↗ source
- Opinion: Why alternative medicine can feel so much better than mainstream health careModern medicine is about making people better — not necessarily making them feel good.